WallStSmart

GE Aerospace (GE)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 36% more annual revenue ($62.58B vs $45.85B). GE leads profitability with a 19.0% profit margin vs 12.4%. GE appears more attractively valued with a PEG of 4.94. GE earns a higher WallStSmart Score of 65/100 (C+).

GE

Buy

65

out of 100

Grade: C+

Growth: 6.7Profit: 8.0Value: 6.7Quality: 5.3
Piotroski: 4/9Altman Z: 1.69

PFE

Hold

49

out of 100

Grade: D+

Growth: 2.0Profit: 6.5Value: 4.7Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GEUndervalued (+21.3%)

Margin of Safety

+21.3%

Fair Value

$376.74

Current Price

$296.56

$80.18 discount

UndervaluedFair: $376.74Overvalued
PFESignificantly Overvalued (-194.9%)

Margin of Safety

-194.9%

Fair Value

$9.25

Current Price

$27.28

$18.03 premium

UndervaluedFair: $9.25Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GE5 strengths · Avg: 8.8/10
Market CapQuality
$306.56B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
44.7%10/10

Every $100 of equity generates 45 in profit

Revenue GrowthGrowth
17.6%8/10

17.6% revenue growth

EPS GrowthGrowth
37.4%8/10

Earnings expanding 37.4% YoY

Free Cash FlowQuality
$1.79B8/10

Generating 1.8B in free cash flow

PFE4 strengths · Avg: 8.3/10
Market CapQuality
$153.36B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
23.9%8/10

Strong operational efficiency at 23.9%

Free Cash FlowQuality
$4.50B8/10

Generating 4.5B in free cash flow

Areas to Watch

GE4 concerns · Avg: 3.5/10
P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

Price/BookValuation
16.7x4/10

Trading at 16.7x book value

Altman Z-ScoreHealth
1.694/10

Distress zone — elevated risk

PEG RatioValuation
4.942/10

Expensive relative to growth rate

PFE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.2%2/10

Revenue declined 1.2%

EPS GrowthGrowth
-21.3%2/10

Earnings declined 21.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : GE

The strongest argument for GE centers on Market Cap, Return on Equity, Revenue Growth. Profitability is solid with margins at 19.0% and operating margin at 19.6%. Revenue growth of 17.6% demonstrates continued momentum.

Bull Case : PFE

The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.

Bear Case : GE

The primary concerns for GE are P/E Ratio, Price/Book, Altman Z-Score.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

GE profiles as a growth stock while PFE is a declining play — different risk/reward profiles.

GE carries more volatility with a beta of 1.37 — expect wider price swings.

GE is growing revenue faster at 17.6% — sustainability is the question.

PFE generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

GE scores higher overall (65/100 vs 49/100), backed by strong 19.0% margins and 17.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE Aerospace

INDUSTRIALS · AEROSPACE & DEFENSE · USA

General Electric Company (GE) is an American multinational conglomerate incorporated in New York City and headquartered in Boston. As of 2018, the company operates through the following segments: aviation, healthcare, power, renewable energy, digital industry, additive manufacturing and venture capital and finance.

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?